At the forefront of this cause are groups dedicated to keeping patients and the people who care for them at the center of the conversation.
Updates
Major depressive disorder (MDD) is a leading cause of disability worldwide. Understanding the impact of MDD on quality of life has become increasingly key in research.
Understanding genetic testing results is complicated, so national guidelines recommend genetic counseling for those considering or undergoing testing. In a recent study, investigators assessed how genetic counseling is utilized in patient care.
Adult vaccination rates in the US are generally low and fall short of public health goals. Given the human and economic burden of vaccine-preventable disease, understanding the factors behind these low coverage rates is critical to improving participation.
There are 3 on-demand treatment therapies to relieve PD off-episodes. Researchers conducted a patient-preference study to understand which aspects of the treatments patients value most.
What do rapidly changing technologies mean to the collection of stated-preference studies – studies that ask individuals what they value in their health and health care?
Insights from our experiences developing medical product dossiers with key considerations for manufacturers planning to develop early dossiers for their products.
EMA has recently launched the MINERVA project aimed at strengthening the use of real-world data in medicines development. RTI Health Solutions researchers will coordinate the project.
Please join Xabier Garcia de Albeniz for this recorded 30-minute case-study workshop on the use of causal inference methods for real-world evidence.
18 years of studies has essentially ruled out any but a small potential increase in risk of osteosarcoma. Due to the strength of the findings and other post-marketing experience, the drug sponsor was able to end their post-market commitment five years ahead of schedule.
The launch of the SIGMA Consortium heralds a new era of collaboration to better understand safety and effectiveness of medical interventions. SIGMA aims to integrate expertise and data from multiple European Research Centres.
We're excited to have reached this milestone in our journey of providing uncompromisingly ethical and objective research to help our clients understand the benefits, risks, value, and potential of their products.
The best practices outlined by this draft guidance should be considered when evaluating PROs intended to support drug submissions as well as medical devices.
RTI-HS will be participating in a feasibility analysis of an EU infrastructure for COVID-19 vaccine monitoring.
This document provides guidance on determining go/no go decisions, understanding potential threats to the validity of the research, and alternative data-collection methods for capturing patient experience data.
RTI has closed on its acquisition of Medical Data Analytics (MDA), a provider of real-world evidence (RWE) generation to the pharmaceutical and biotechnology industry. The acquisition expands existing services of RTI Health Solutions.
Recurring ear infections in children are not only frustrating and painful–they can also cause serious complications. If antibiotics do not successfully treat an ear infection or if infections continue to occur, a physician may recommend the insertion of ear tubes.
Answers to key questions about the communication of information for unapproved products as well as unapproved uses of approved products.
Our new office in Lyon, France, enhances our capabilities in real-world evidence generation. Welcome to the newest members of the RTI Health Solutions team.
In this study, we explored an alternative to cloning, based on randomly allocating people to either strategy.
As a result of these findings, a validated coding algorithm updated to ICD-10 codes to identify psychosis associated with dementia is recommended.
Josephine Mauskopf has been awarded the Marilyn Dix Smith Leadership Award by ISPOR.
Patients with drug-resistant epilepsy (DRE) utilize more health care resources and face higher costs than patients who can control their condition with anti-epileptic drugs (AEDs). Despite the long-term proven effectiveness of vagus nerve stimulation (VNS), the treatment is currently underutilized.
The recent FDA guidance opens up a communication channel that hasn’t existed before. Manufacturers who discuss reimbursement with payers before approval may improve their product access.
The AD PACE initiative is a first-of-its-kind collaboration among pharmaceutical companies, advocacy organizations, academic institutions and care services companies to understand which outcomes matter to individuals and to use that information to develop treatments to improve patients’ lives.